Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease

NCT02101164 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Metastatic Bone Disease

Interventions

BIOLOGICAL: denosumab
DRUG: pamidronate

Sponsor

Amgen